{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-108474","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.903036+00:00","generated_at":"2026-05-15T11:49:22.519015+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Zachary Prensky to retire from LB Pharmaceuticals board at 2026 annual meeting","bullets":["Zachary Prensky notified board on March 13, 2026; will not stand for reelection at the 2026 annual meeting.","Prensky remains on board and Nominating & Governance Committee until the meeting concludes.","Decision was not due to any disagreement with the company; he will provide consulting services post-retirement.","Amendment to Transition Agreement allows unvested stock options to continue vesting during the consulting term."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-108474","json":"https://secwatch.observer/filing/0001193125-26-108474.json","markdown":"https://secwatch.observer/filing/0001193125-26-108474.md","text":"https://secwatch.observer/filing/0001193125-26-108474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526108474/0001193125-26-108474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526108474/d105454d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:49:22.519015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}